Last reviewed · How we verify
Monthly ADX-2191 injection
ADX-2191 is a reactive aldehyde species (RAS) scavenger that binds and neutralizes pathogenic aldehydes implicated in ocular surface inflammation and disease.
ADX-2191 is a reactive aldehyde species (RAS) scavenger that binds and neutralizes pathogenic aldehydes implicated in ocular surface inflammation and disease. Used for Dry eye disease, Ocular surface inflammation.
At a glance
| Generic name | Monthly ADX-2191 injection |
|---|---|
| Sponsor | Aldeyra Therapeutics, Inc. |
| Drug class | Reactive aldehyde scavenger |
| Target | Reactive aldehyde species (RAS) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
The drug works by sequestering reactive aldehyde species that accumulate in inflammatory conditions of the eye. By reducing aldehyde-mediated damage and inflammation, ADX-2191 aims to restore ocular surface homeostasis and reduce symptoms associated with dry eye disease and other anterior segment inflammatory conditions. The monthly injection formulation provides sustained local delivery to the eye.
Approved indications
- Dry eye disease
- Ocular surface inflammation
Common side effects
- Conjunctival injection
- Eye irritation
- Ocular discomfort
Key clinical trials
- A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma (PHASE3)
- A Study in Subjects With Retinitis Pigmentosa (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |